The requirement for cyclin D function in tumor maintenance.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Cell

• Publication date

  2012-10-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccr.2012.09.015PMID 23079655PMCID PMC3487466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclin D as a therapeutic target in cancer

  2011influential reference
• A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.

  2011influential reference
• Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.

  2011cited by this paper
• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  2010influential reference
• Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence.

  2010cited by this paper
• Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.

  2010cited by this paper
• Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells.

  2009cited by this paper
• FoxM1, a critical regulator of oxidative stress during oncogenesis

  2009cited by this paper
• Proapoptotic function of the retinoblastoma tumor suppressor protein.

  2009cited by this paper
• Cell cycle, CDKs and cancer: a changing paradigm

  2009cited by this paper
• E2F1-3 Switch from Activators in Progenitor Cells to Repressors in Differentiating Cells

  2009cited by this paper
• Division and apoptosis of E2f-deficient retinal progenitors

  2009influential reference
• A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.

  2009cited by this paper
• In Vivo Pharmacodynamic Imaging of Proteasome Inhibition

  2009cited by this paper
• Senescence-messaging secretome: SMS-ing cellular stress

  2009cited by this paper
• Activity-dependent regulation of inhibitory synapse development by Npas4

  2008cited by this paper
• FoxM1c Counteracts Oxidative Stress-induced Senescence and Stimulates Bmi-1 Expression*

  2008cited by this paper
• Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1

  2008cited by this paper
• FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

  2007cited by this paper
• CDK4 and CDK6 Delay Senescence by Kinase-Dependent and p16INK4a-Independent Mechanisms

  2007cited by this paper
• Identification of a Conserved Negative Regulatory Sequence That Influences the Leukemogenic Activity of NOTCH1

  2006cited by this paper
• A unique function for cyclin D3 in early B cell development

  2006cited by this paper
• Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.

  2006influential reference
• Essential Role for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil Granulocytes

  2006cited by this paper
• Requirement for CDK4 kinase function in breast cancer.

  2006cited by this paper
• Cyclins and cdks in development and cancer: a perspective

  2005influential reference
• Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss.

  2005cited by this paper
• Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.

  2005cited by this paper
• Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

  2004cited by this paper
• Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

  2004cited by this paper
• Differential regulation of apoptotic genes by Rb in human versus mouse cells

  2004cited by this paper
• Living with or without cyclins and cyclin-dependent kinases.

  2004cited by this paper
• Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice

  2004cited by this paper
• Minireview: Cyclin D1: normal and abnormal functions.

  2004influential reference
• Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry

  2003cited by this paper
• Cyclin D2 and p27 Are Tissue-Specific Regulators of Tumorigenesis in Inhibin α Knockout Mice

  2003cited by this paper
• GeneMerge - Post-genomic Analysis, Data Mining, and Hypothesis Testing

  2003cited by this paper
• Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence.

  2003cited by this paper
• Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin alpha knockout mice.

  2003cited by this paper
• Requirement for cyclin D3 in lymphocyte development and T cell leukemias.

  2003influential reference
• Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E

  2002influential reference
• Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

  2002cited by this paper
• Transcription: Sibling rivalry in the E2F family

  2002cited by this paper
• Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

  2001cited by this paper
• Specific protection against breast cancers by cyclin D1 ablation

  2001influential reference
• Genetics and biology of adult human male germ cell tumors.

  2000cited by this paper
• Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

  1998cited by this paper
• Inducible gene targeting in mice

  1995cited by this paper
• Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

  1995cited by this paper
• Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

  1995cited by this paper
• Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene.

  1994cited by this paper
• Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

  1994cited by this paper
• Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice.

  1994cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper
• Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence

  year unknowncited by this paper

• Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

  2026cites this paper
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.

  2025cites this paper
• Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.

  2025cites this paper
• Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report

  2025cites this paper
• Network-based analysis and experimental validation of identified natural compounds from Yinchen Wuling San for acute myeloid leukemia

  2025cites this paper
• Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.

  2025cites this paper
• Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update

  2025cites this paper
• The Central Role of Pin1 in Age-Related Cancer Signaling Pathways.

  2025cites this paper
• Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report

  2025cites this paper
• Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

  2025cites this paper
• Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors

  2025cites this paper
• Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury

  2025cites this paper
• Targeting the cell-cycle machinery for cancer therapy.

  2025cites this paper
• Advances in combination therapy for the treatment of estrogen receptor positive breast cancer

  2025cites this paper
• ZNF652 exerts a tumor suppressor role in lung cancer by transcriptionally downregulating cyclin D3

  2024cites this paper
• Antineoplastic effect of compounds C14 and P8 on TNBC and radioresistant TNBC cells by stabilizing the K-Ras4BG13D/PDE6δ complex

  2024cites this paper
• Synergistic Effect of Resveratrol and Paclitaxel in the Treatment of Malignant Pleural Mesothelioma

  2024cites this paper
• Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.

  2024cites this paper
• Kinases in motion: impact of protein and small molecule interactions on kinase conformations

  2024cites this paper
• Impact of protein and small molecule interactions on kinase conformations

  2024cites this paper
• In vitro and in vivo effects of curcumin on oral cancer: a systematic review

  2024cites this paper
• Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.

  2023cites this paper
• Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

  2023cites this paper
• Orotic acid induces apoptotic death in ovarian adult granulosa tumour cells and increases mitochondrial activity in normal ovarian granulosa cells.

  2023cites this paper
• Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia

  2023cites this paper
• CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis.

  2023cites this paper
• An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia

  2023cites this paper
• Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

  2023cites this paper
• Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma

  2023cites this paper
• CDK6: an attractive therapeutic target for T-ALL/LBL

  2023cites this paper
• On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

  2023cites this paper
• Changes in the mammary gland during aging and its links with breast diseases

  2023influential citation
• Targeting Cyclin Dependent Kinase 4/6 for Cancer Therapy

  2023cites this paper
• A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction

  2023cites this paper
• INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

  2023influential citation
• The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer

  2023cites this paper
• Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance

  2023cites this paper
• Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest.

  2023cites this paper
• The Dance Between Tumor Molecular Biology and Antitumor Immune Response.

  2023cites this paper
• Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

  2023cites this paper
• Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING‐dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer

  2023cites this paper
• Cyclin‐dependent kinases: Masters of the eukaryotic universe

  2023cites this paper
• The molecular mechanism of neutrophil extracellular traps and its role in bone and joint disease

  2023cites this paper
• Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase

  2022cites this paper
• Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles

  2022cites this paper
• Extraction Optimization, Structural Characterization, and Anti-Hepatoma Activity of Acidic Polysaccharides From Scutellaria barbata D. Don

  2022cites this paper
• Emerging Therapies for Breast Cancer.

  2022cites this paper
• NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition

  2022cites this paper
• PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer.

  2022cites this paper
• Thermo-sensitive hydrogel-mediated Locally sequential release of doxorubicin and Palbociclib for chemo-immunotherapy of osteosarcoma

  2022cites this paper
• Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.

  2022cites this paper
• Targeting CDK4 and CDK6 in cancer

  2022cites this paper
• Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

  2022cites this paper
• Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects

  2022cites this paper
• Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

  2022cites this paper
• The Renaissance of Cyclin Dependent Kinase Inhibitors

  2022cites this paper
• In vivo assessment of simultaneous G1 cyclins silencing by a tumor-specific bidirectional promoter on the mammary tumor in nude mice

  2022cites this paper
• Melatonin Induces Cell Cycle Arrest, Inhibits Cell Proliferation and Accelerates Apoptosis by Modulation of CDK4 in NSCLC

  2022cites this paper
• New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia

  2022cites this paper
• CDK4 and CDK6 kinases: From basic science to cancer therapy

  2022cites this paper
• Regulation of Cyclin D1 Degradation by Ubiquitin Specific Protease 27X is Critical for Cancer Cell Proliferation and Tumor Growth.

  2022cites this paper
• Science Journals — AAAS

  2022cites this paper
• From cyclins to CDKIs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation.

  2022cites this paper
• Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors.

  2022cites this paper
• Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract

  2022cites this paper
• Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer.

  2022cites this paper
• Prediction of allosteric druggable pockets of cyclin-dependent kinases

  2022cites this paper
• CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review

  2022cites this paper
• LINC00514 facilitates cell proliferation, migration, invasion, and epithelial-mesenchymal transition in non-small cell lung cancer by acting on the Wnt/β-catenin signaling pathway

  2022cites this paper
• CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia

  2022cites this paper
• The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia

  2022cites this paper
• Oncogenic signals prime cancer cells for toxic cell growth during a G1 cell cycle arrest

  2022cites this paper
• Biomarkers involved in the proliferation of the odontogenic keratocyst, glandular odontogenic cyst and botryoid odontogenic cyst

  2022cites this paper
• 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor

  2022cites this paper
• TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity

  2021cites this paper
• Curcumin and Afatinib Synergistically Inhibit Growth of Human Osteosarcoma Cells by Inhibition of Matrix Metallo Proteinases, Mitogen Activated kinases 1-4, and Reactive Oxygen Species

  2021cites this paper
• Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27

  2021cites this paper
• The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer

  2021cites this paper
• Feedback, Crosstalk and Competition: Ingredients for Emergent Non-Linear Behaviours in the PI3K/mTOR Signalling Network

  2021cites this paper
• CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy

  2021cites this paper
• Feedback, Crosstalk and Competition: Ingredients for Emergent Non-Linear Behaviour in the PI3K/mTOR Signalling Network

  2021cites this paper
• Nuclear PFKP promotes CXCR4 dependent T cell acute lymphoblastic leukemia infiltration.

  2021cites this paper
• Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment

  2021cites this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cites this paper
• Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches

  2021cites this paper
• T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo

  2021cites this paper
• Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia

  2021cites this paper
• A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program

  2021cites this paper
• Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models

  2021cites this paper
• Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

  2021cites this paper
• Expression of cyclin-dependent kinases and their clinical significance with immune infiltrates could predict prognosis in colorectal cancer

  2021cites this paper
• Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

  2021cites this paper
• Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives

  2021cites this paper
• Targeting cell-cycle machinery in cancer.

  2021cites this paper
• How selective are clinical CDK4/6 inhibitors?

  2020cites this paper
• CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

  2020cites this paper
• Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.

  2020cites this paper
• Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition

  2020cites this paper
• An evaluation of palbociclib as a breast cancer treatment option: a current update

  2020cites this paper
• Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

  2020cites this paper